Symbols

XAIR

Beyond Air·NASDAQ

--(--)

XAIR fundamentals

XAIR Q3 2026 Earnings

Beyond Air (XAIR) released its earnings on Feb 13, 2026: revenue was 2.19M (YoY +104.29%), beat estimates; EPS was -0.85 (YoY +71.67%), missed estimates.

Revenue / YoY

2.19M

+104.29%

EPS / YoY

-0.85

+71.67%

Report date

Feb 13, 2026

XAIR Earnings Call Summary for Q3,2026

Revenue Growth: 105% YoY to $2.2M, driven by Gen I LungFit PH adoption
Gen II Launch: FDA approval expected by end-2026 with enhanced transport capabilities
Strategic Restructuring: NeuroNOS sale provides $31.5M milestone potential
Financial Health: $17.8M cash, 36% OpEx reduction, 13.6% gross margin
Pipeline Progress: Beyond Cancer Phase Ib trial for nitric oxide therapy in glioblastoma and autism

Earnings

EPS

Revenue

Revenue & Expenses

XAIR has released its 2026 Q3 earnings report, with revenue of 2.19M, reflecting a YoY change of 104.66%, and net profit of -7.63M, showing a YoY change of 42.77%. The Sankey diagram below clearly presents XAIR's revenue sources and cost distribution.

Key Indicators

Beyond Air (XAIR) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Beyond Air (XAIR)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Beyond Air (XAIR)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Beyond Air (XAIR)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown